



February 4, 2025

Ref:- GHL/2024-25/EXCH/106

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Dear Sir(s),

We would like to inform you that the Board of Directors of Global Health Limited ('GHL/Company/Medanta') at its meeting held today i.e. *Tuesday, February 4, 2025*, has *inter alia*, approved:


1) Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine months ended December 31, 2024 ('Results');


The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiok & Co LLP, Chartered Accountants thereon, are enclosed herewith as **Annexure A**, pursuant to Regulation 33 of the Listing Regulations.

2) The recommendation to the Members for re-appointment of Ms. Praveen Mahajan (DIN:07138514) as an Independent Director of the Company, not liable to retire by rotation, to hold office for a second term of 5 (five) consecutive years; and

The Company shall seek the approval of Members through Postal Ballot and the Notice of Postal Ballot, will be sent to all the Members of the Company whose names appear on the Register of Members/List of Beneficial Owners as received from Depositories, as on **Friday, February 7, 2025 ('Cut-off date')**.

The details pursuant to Regulation 30 of Listing Regulations are given in **Annexure B**.





Global Health L i m i t e d

3) Execution of a long term lease deed for taking up a newly constructed hospital with approximate bed capacity of 110 beds in close proximity to the existing facility of the Company at Ranchi. The details pursuant to Regulation 30 of Listing Regulations are given in **Annexure C**.

The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges.

The meeting of the Board of Directors commenced at 02.00 P.M. and concluded at 04:00 P.M.


Thanking You,

For Global Health Limited

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035



Encl: a/a



Walker Chandlok & Co LLP
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II,
Gurugram - 122 002
Haryana, India
T +91 124 462 8099
F +91 124 462 8001

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 31 December 2024 and the consolidated year to date results for the period 01 April 2024 to 31 December 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida, and Pune

Walker Chandlok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandio & Co LLP

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandio & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Tarun

Tarun Gupta
Partner
Membership No. 507892



UDIN: 25507892BMNSKJ4379

Place: Gurugram
Date: 04 February 2025

Walker Chandniok & Co LLP

Annexure 1 to the Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

List of entities included in the Statement

S. No.	Name	Relationship with the Holding Company
1	Medanta Holdings Private Limited	Wholly owned subsidiary
2	Global Health Patliputra Private Limited	Wholly owned subsidiary
3	GHL Pharma & Diagnostic Private Limited (Formerly known as Global Health Pharmaceuticals Private Limited)	Wholly owned subsidiary
4	GHL Hospital Limited (incorporated on 11 December 2023)	Subsidiary
5	Global Health Institute of Medical Sciences Foundation (incorporated on 30 March 2024)	Wholly owned subsidiary



Global Health Limited

Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India

Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India

CIN:L85110DL2004PLC128319

Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: <https://www.medanta.org>

Statement of consolidated unaudited financial results for the quarter and nine months ended 31 December 2024

(₹ in millions, unless otherwise stated)

S. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31 December 2024 (Unaudited)	30 September 2024 (Unaudited)	31 December 2023 (Unaudited)	31 December 2024 (Unaudited)	31 December 2023 (Unaudited)	31 March 2024 (Audited)
	Income						
I	Revenue from operations	9,434.36	9,565.55	8,364.54	27,610.68	24,664.80	32,751.11
II	Other income	160.24	182.16	180.79	561.67	472.42	746.64
	Total income	9,594.60	9,747.71	8,545.33	28,172.35	25,137.22	33,497.75
	Expenses						
III	Cost of materials consumed	2,066.01	2,042.75	1,722.40	5,984.81	5,111.69	6,876.86
	Purchases of stock-in-trade	206.99	281.54	181.32	719.50	564.03	739.68
	Changes in inventories of stock-in-trade	19.04	(44.47)	2.96	(43.81)	(19.53)	(22.94)
	Employee benefits expense	2,050.17	2,142.86	1,850.56	6,204.88	5,470.57	7,348.58
	Finance costs	162.75	159.75	176.79	502.29	556.84	739.13
	Depreciation and amortisation expense	484.46	494.30	439.82	1,444.94	1,272.75	1,727.28
	Impairment losses on financial assets	34.11	60.92	55.34	144.06	175.57	293.13
	Retainers and consultants fee	1,249.43	1,223.29	1,116.84	3,657.51	3,189.46	4,270.28
	Other expenses	1,430.96	1,575.78	1,275.65	4,419.98	3,975.72	5,254.76
	Total expenses	7,703.92	7,936.72	6,821.68	23,034.16	20,297.10	27,226.76
IV	Profit before tax	1,890.68	1,810.99	1,723.65	5,138.19	4,840.12	6,270.99
	Tax expense						
	Current tax	396.59	486.08	487.43	1,246.88	1,385.43	1,777.38
	Tax pertaining to earlier years	-	-	12.35	-	12.35	12.35
	Deferred tax charge/(credit)	65.51	16.73	(11.54)	91.91	(64.79)	(299.34)
V	Profit after tax	1,428.58	1,308.18	1,235.41	3,799.40	3,507.13	4,780.60
	Other comprehensive income						
	(i) Items that will not be reclassified to statement of profit or loss	38.36	10.07	6.82	21.33	(12.62)	(12.69)
	(ii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(9.53)	(2.59)	(1.62)	(5.29)	3.33	3.31
VI	Total other comprehensive income	28.83	7.48	5.20	16.04	(9.29)	(9.38)
VII	Total comprehensive income	1,457.41	1,315.66	1,240.61	3,815.44	3,497.84	4,771.22
	Profit after tax attributable to:						
	(i) Owners of the Holding Company	1,429.07	1,308.44	1,236.41	3,800.37	3,508.13	4,781.94
	(ii) Non-controlling interests	(0.49)	(0.26)	(1.00)	(0.97)	(1.00)	(1.34)
	Other comprehensive income attributable to:						
	(i) Owners of the Holding Company	28.83	7.48	5.20	16.04	(9.29)	(9.38)
	(ii) Non-controlling interests	-	-	-	-	-	-
	Total comprehensive income attributable to:						
	(i) Owners of the Holding Company	1,457.90	1,315.92	1,241.61	3,816.41	3,498.84	4,772.56
	(ii) Non-controlling interests	(0.49)	(0.26)	(1.00)	(0.97)	(1.00)	(1.34)
VIII	Paid-up equity share capital (face value of ₹ 2 each)	537.17	537.09	536.85	537.17	536.85	537.01
IX	Reserves (other equity)						28,519.26
X	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters and nine months)						
	Basic (₹ per share)	5.32	4.87	4.61	14.14	13.07	17.80
	Diluted (₹ per share)	5.32	4.87	4.60	14.14	13.06	17.80

See accompanying notes to the consolidated unaudited financial results



Global Health Limited

Notes to the consolidated unaudited financial results:

- 1 The above consolidated financial results of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred as 'the Group') for the quarter and nine months ended 31 December 2024 has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 04 February 2025 and a limited review of the same has been carried out by the statutory auditors.
- 2 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The chief operating decision maker (CODM) examines the Group's performance from a service perspective and has identified the Healthcare services as single business segment.
- 4 The Board of Directors of the Holding Company at their meeting held on 21 March 2024 had approved the Scheme of Amalgamation between Medanta Holdings Private Limited, wholly owned subsidiary, (Transferor Company) and the Holding Company (Transferee Company) and their respective members and creditors under section 230 to 232 of the Companies Act, 2013. The Holding Company had filed the application with National Company Law Tribunal, New Delhi ('NCLT') on 06 May 2024. Pursuant to the NCLT order dated 12 June 2024, meetings of the unsecured creditors and shareholders of the Holding Company have been held on 03 August 2024 where the Scheme was approved and accordingly, Holding Company had filed the second motion petition with NCLT on 14 August 2024. Subsequent to the period ended 31 December 2024, the hearing took place on 08 January 2025 wherein the NCLT has reserved the order.
- 5 During the nine months ended 31 December 2024, the Holding Company has acquired land parcel, on lease basis, situated at Mauje-Oshiwara, Jogeshwari, Mumbai, offered by Mumbai Housing and Area Development Authority (MHADA).
- 6 During the quarter ended 31 December 2024, the Holding Company has executed definitive agreement with Dr. Narayan Dutt Shrimali Foundation International Charitable Trust Society (Society) to operate and manage ~750 bedded hospital in Pitampura, New Delhi.
- 7 The Board of Directors and the shareholders of the Holding Company on 14 November 2024 and 27 December 2024 respectively, approved Global Health Limited Employees Long-Term Share Based Incentive Plan – 2024 ("GHL Plan 2024") for eligible employees of the Holding Company and its subsidiaries and associates. Under the GHL Plan 2024, which will be implemented through a Trust, the maximum number of shares that may be allotted shall not exceed 1,750,000 equity shares of ₹ 2 each through primary issuance and 5,370,147 equity shares (i.e. 2% of paid up capital of the Holding Company as on 31 March 2024), through secondary acquisition.
- 8 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited



Dr. Naresh Trehan
Chairman and Managing Director

Place : Gurugram
Date : 04 February 2025



Walker ChandioK & Co LLP
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II,
Gurugram - 122 002
Haryana, India
T +91 124 462 8099
F +91 124 462 8001

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Global Health Limited ('the Company') for the quarter ended 31 December 2024 and the year to date results for the period 01 April 2024 to 31 December 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida, and Pune

Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandiook & Co LLP

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Tarun

Tarun Gupta
Partner
Membership No. 507892



UDIN: 25507892BMNSKI2809

Place: Gurugram
Date: 04 February 2025

Global Health Limited

Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India

Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India

CIN:L85110DL2004PLC128319

Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: <https://www.medanta.org>

Statement of standalone unaudited financial results for the quarter and nine months ended 31 December 2024

(₹ in millions, unless otherwise stated)

S No.	Particulars	Quarter ended			Nine months ended		Year ended
		31 December 2024	30 September 2024	31 December 2023	31 December 2024	31 December 2023	31 March 2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income						
I	Revenue from operations	6,244.04	6,646.06	5,648.40	19,004.59	17,013.63	22,800.08
II	Other income	221.66	235.79	226.71	724.43	703.21	1,028.68
	Total income	6,465.70	6,881.85	5,875.11	19,729.02	17,716.84	23,828.76
	Expenses						
III	Cost of materials consumed	1,489.24	1,521.11	1,254.47	4,415.96	3,723.51	5,061.46
	Purchases of stock-in-trade	110.93	117.83	101.11	345.67	323.87	423.39
	Changes in inventories of stock-in-trade	(2.74)	2.15	5.18	(5.83)	(4.65)	(6.25)
	Employee benefits expense	1,582.30	1,680.98	1,473.05	4,838.29	4,418.95	5,910.62
	Finance costs	59.41	53.68	57.59	172.61	182.46	244.57
	Depreciation and amortisation expense	234.39	249.09	217.30	716.51	637.01	870.90
	Impairment losses on financial assets	33.14	56.12	50.79	125.29	169.51	277.32
	Retainers and consultants fee	649.39	658.30	605.42	1,961.26	1,731.84	2,332.12
	Other expenses	986.54	1,106.50	901.48	3,102.64	2,899.30	3,827.92
	Total expenses	5,142.60	5,445.76	4,666.39	15,672.40	14,081.80	18,942.05
IV	Profit before tax	1,323.10	1,436.09	1,208.72	4,056.62	3,635.04	4,886.71
V	Tax expense						
	Current tax	294.68	413.82	345.20	1,029.97	1,041.14	1,383.40
	Tax pertaining to earlier years	-	-	12.35	-	12.35	12.35
	Deferred tax charge/(credit)	35.37	(22.39)	(22.27)	26.10	(104.98)	(117.95)
VI	Profit after tax	993.05	1,044.66	873.44	3,000.55	2,686.53	3,608.91
VII	Other comprehensive income						
	A (i) Items that will not be reclassified to statement of profit or loss	35.86	9.51	5.72	19.99	(14.02)	(14.91)
	(ii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(9.02)	(2.40)	(1.44)	(5.03)	3.53	3.75
	Total other comprehensive income	26.84	7.11	4.28	14.96	(10.49)	(11.16)
VIII	Total comprehensive income	1,019.89	1,051.77	877.72	3,015.51	2,676.04	3,597.75
IX	Paid-up equity share capital (face value of ₹ 2 each)	537.17	537.09	536.85	537.17	536.85	537.01
X	Reserves (other equity)						27,950.97
XI	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters and nine months)						
	Basic (₹ per share)	3.70	3.89	3.25	11.17	10.01	13.44
	Diluted (₹ per share)	3.70	3.89	3.25	11.17	10.00	13.44

See accompanying notes to the standalone unaudited financial results

(This space has been intentionally left blank)



Global Health Limited


Notes to the standalone unaudited financial results:

- 1 The above standalone financial results for the quarter and nine months ended 31 December 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 04 February 2025 and a limited review of the same has been carried out by the statutory auditors.
- 2 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The chief operating decision maker (CODM) examines the Company's performance from a service perspective and has identified the Healthcare services as single business segment.
- 4 The Board of Directors of the Company at their meeting held on 21 March 2024 had approved the Scheme of Amalgamation between Medanta Holdings Private Limited, wholly owned subsidiary, (Transferor Company) and the Company (Transferee Company) and their respective members and creditors under section 230 to 232 of the Companies Act, 2013. The Company had filed the application with National Company Law Tribunal, New Delhi ('NCLT') on 06 May 2024. Pursuant to the NCLT order dated 12 June 2024, meeting of the unsecured creditors and shareholders of the Company have been held on 03 August 2024 where the Scheme was approved and accordingly, Company had filed the second motion petition with NCLT on 14 August 2024. Subsequent to the period ended 31 December 2024, the hearing took place on 08 January 2025 wherein the NCLT has reserved the order.
- 5 During the period ended 31 December 2024, the Company has acquired land parcel, on lease basis, situated at Mauje-Oshiwara, Jogeshwari, Mumbai, offered by Mumbai Housing and Area Development Authority (MHADA).
- 6 During the quarter and period ended 31 December 2024, the Company has executed definitive agreement with Dr. Narayan Dutt Shrimali Foundation International Charitable Trust Society (Society) to operate and manage ~750 bedded hospital in Pitampura, New Delhi.
- 7 The Board of Directors and the shareholders of the Company on 14 November 2024 and 27 December 2024 respectively, approved Global Health Limited Employees Long-Term Share Based Incentive Plan – 2024 ("GHL Plan 2024") for eligible employees of the Holding Company and its subsidiaries and associates. Under the GHL Plan 2024, which will be implemented through a Trust, the maximum number of shares that may be allotted shall not exceed 1,750,000 equity shares of ₹ 2 each through primary issuance and 5,370,147 equity shares (i.e. 2% of paid up capital of the Holding Company as on 31 March 2024), through secondary acquisition.
- 8 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited

Place : Gurugram

Date : 04 February 2025


Dr. Naresh Trehan
Chairman and Managing Director



Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Annexure B

S. No.	Particulars	Information of event
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	Re-appointment of Ms. Praveen Mahajan as a Non-executive Independent Director of the Company for a second term of 5 (five) consecutive years with effect from July 10, 2025, subject to approval of the shareholders.
3.	Brief profile (in case of appointment);	Ms. Mahajan holds a bachelor's and masters' degree in English and History from the Punjab University, Chandigarh, India. She has over 37 years of distinguished service in the Indian Revenue Service, served as the first woman Chairperson of the Central Board of Excise and Customs (CBEC). She played a pivotal role in the formulation and implementation of India's Goods and Services Tax (GST), contributing to the Constitutional Amendment Bill, model GST law, and the establishment of the GST Network (GSTN). Her expertise spans public finance, tax policy, enforcement, and regulatory frameworks, with a deep understanding of industries such as telecom, banking, real estate, and IT. Following her tenure at CBEC, she served as a Member (Administrative) at the Central Administrative Tribunal, delivering significant judgments on public service rights. In recognition of her extraordinary service, she received the Presidential Award for Devotion to Duty. Her career reflects a blend of strategic leadership, regulatory expertise, and dedication to public service.
4.	Disclosure of relationships between directors (in case of appointment of a Director)	Mr. Mahajan is not related to any Director of the Company.
5.	Information required pursuant to BSE and National Stock Exchange of India Ltd. circulars dated June 30, 2018	Mr. Mahajan is not debarred from holding the office of director pursuant to any SEBI order or any other authority.



Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Annexure C

a) Capacity Addition

S. No	Particulars	Details
1.	Existing capacity	Global Health Limited capacity as on December 31, 2024 is over 3,000 beds
2.	Existing capacity utilization	Consolidated Capacity Utilization for Q3 FY25 was ~ 64%
3.	Proposed capacity addition	A newly built ~110 bed hospital, ready for operationalization is proposed to be added to GHIL under the Lease Agreement.
4.	Period within which the proposed capacity is to be added	The proposed hospital is a newly built ~110 bedded hospital and shall be ready for an operationalization within 6 months, subject to necessary statutory and customary approvals.
5.	Investment required	The hospital constructed by SAC Hospital Management and Consultancy Service Private Limited. Medanta is expected to incur a project capex of upto Rs. 50 crores for medical and other equipment and to run the hospital.
6.	Mode of financing	To be funded by internal accruals
7.	Rationale	The hospital is strategically located just 1.2 km from Medanta Ranchi, enabling seamless integration and operational synergies. The newly built facility is designed with a primary focus on high-end tertiary care, addressing a critical gap currently unmet at Medanta Ranchi. This lease agreement allows Medanta to further strengthen its presence in the East region and deliver the highest standard of tertiary and quaternary care.

Rajan



b) Arrangement for Strategic Tie Up

S. No	Particulars	Details
1.	Name of the entity(ies) with whom agreement/JV is signed;	SAC Hospital Management and Consultancy Service Private Limited
2.	Area of agreement/JV;	Lease agreement with SAC Hospital Management and Consultancy Service Private Limited (Lessor) to operate and manage a ~110 beds super specialty hospital in Ranchi, Jharkhand.
3.	Domestic/international;	Domestic
4.	Share exchange ratio /JV ratio;	Not Applicable
5.	Scope of business operation of agreement /JV;	The Lessor, in consideration of the Lease Rent grants unto the Lessee a lease of the Land along with the Hospital Building consisting of ~110 beds. Medanta to invest in medical equipment and to operate/manage the hospital.
6.	Details of consideration paid / received in agreement /JV;	Under the agreement, the Lessor will be eligible to receive the lease rent, as agreed between the parties.
7.	Significant terms and conditions of agreement /JV in brief;	Medanta will have full control over day to day running of the business under lease agreement for an initial term of 15 years further extendable for another 2 terms of 15 years at the sole discretion of Medanta.
8.	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The transaction is not a Related Party Transaction
9.	Size of the entity(ies)	Not Applicable
10.	Rationale and benefit expected	The hospital is strategically located just 1.2 km from Medanta Ranchi, enabling seamless integration and operational synergies. The newly built facility is designed with a primary focus on high-end tertiary care, addressing a critical gap currently unmet at Medanta Ranchi. This lease agreement allows Medanta to further strengthen its presence in the East region and deliver the highest standard of tertiary and quaternary care.